Meeting Report
Molecular Testing in Hematologic Malignancies
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
From University of California San Francisco
Presenter’s disclosure of conflicts of interest is found at the end of this article.
J Adv Pract Oncol 2022;13(3):324–327 |
https://doi.org/10.6004/jadpro.2022.13.3.29 |
© 2022 Harborside™
ABSTRACT
Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, reviewed key concepts for diagnostic testing with a focus on molecular testing (including cytogenetics, FISH, PCR, and next-generation sequencing) and discussed how to interpret the results for hematologic malignancies to inform prognosis as well as treatment.
Erratum: "Nonsense variant" was previously described as "does not have any significant consequences because an abnormal protein is not made." It has now been corrected to: “A genetic alteration that causes the premature termination of a protein." In addition, "mutation" has been replaced with "variant" throughout the article when referring to a change in the DNA sequence. Please see the Letter to the Editor for more information.
For access to the full length article, please
sign in.
